Infliximab: a promising alternative therapy for refractory arthritis/urethritis/conjunctivitis triad.
de Carvalho
Jozélio Freire
JF
Rheumatology Division, Faculty of Medicine, University of Sao Paulo, and Center for High Cost Medicines (CEDMAC), Sao Paulo, Brazil.
Ribeiro
Ana Cristina de Medeiros
AC
de Moraes
Júlio Cezar Bertacini
JC
Gonçalves
Carla
C
Goldenstein-Schainberg
Cláudia
C
Bonfá
Eloísa
E
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D016918:Arthritis, Reactive / Q000150:complications / Q000188:drug therapy*; D003231:Conjunctivitis / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D014526:Urethritis / Q000150:complications / Q000188:drug therapy*
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000069285:Infliximab